- Human pathology

Home > E. Pathology by systems > Digestive system > Liver and pancreatobiliary system > Pancreas > KRAS/TP53-associated pancreatic adenocarcinoma

KRAS/TP53-associated pancreatic adenocarcinoma

Thursday 2 March 2017

KRAS/TP53-mutated pancreatic adenocarcinoma ; KRAS/TP53-mutant pancreatic adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is a rapidly progressing disease associated with less than 10% 5-year survival rate.

See also

- TP53
- pancreatic adenocarcinoma

Paywall references

- p53 mutations cooperate with oncogenic Kras to promote adenocarcinoma from pancreatic ductal cells. Bailey JM, Hendley AM, Lafaro KJ, Pruski MA, Jones NC, Alsina J, Younes M, Maitra A, McAllister F, Iacobuzio-Donahue CA, Leach SD. Oncogene. 2016 Aug 11;35(32):4282-8. doi : 10.1038/onc.2015.441
PMID: 26592447